NCT00408902View on ClinicalTrials.gov

Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

December 31, 2008

Conditions
Clear Cell Renal Cell CarcinomaRecurrent Renal Cell CancerStage IV Renal Cell Cancer
Interventions
DRUG

tandutinib

Given orally, 500 mg bid daily

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

44106

Case Western Reserve University, Cleveland

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00408902 - Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter